ew solutions cut observational research production from months to minutes, while maintaining precision, transparency and producing rigorous evidence for healthcare
Atropos Health, leader in evidence generation for healthcare, today announced the launch of the Geneva OS™(Generative Evidence Acceleration Operating System) and the ChatRWD™ (Real World Data) application, the first Generative AI application incorporating direct Chat-to-Database capability, to help healthcare and life science leaders advance and accelerate evidence generation. The new offering will enable non technical users to generate publication grade Observational Research studies leveraging deidentified patient level real world data from the Atropos Evidence Network in a matter of minutes, saving organizations valuable time, money, and staffing resources.
“Evidence generation is the key to improving care and outcomes. The Geneva OS represents a critical infrastructure layer for the healthcare ecosystem that can rapidly, accurately, and transparently convert healthcare data into personalized evidence,” said Brigham Hyde, Co-Founder and CEO of Atropos Health. “In addition, our ChatRWD user application represents an evolutionary jump in the speed and user experience by which evidence can be generated. Building on the core technology behind our Green Button Informatics Consult Service, users can now generate publication grade Real World Evidence from hundreds of millions of patients’ deidentified medical records in minutes.”
Atropos Health’s Geneva OS and ChatRWD application were designed with clinicians, researchers, and drug developers in mind, to close the global evidence gap while accelerating study and decision-making timelines. Users can now access Geneva OS and ChatRWD alongside Atropos’ existing evidence solutions – the Green Button Informatics Consult Service, Atropos Evidence Network, and Atropos Evidence Library.
The launch of Geneva OS and ChatRWD comes at the same time as healthcare and life science leaders grapple with the safety and ethics of leveraging generative AI. They are right to be concerned; one study published by Stanford’s Human-Centered AI Institute as well as covered in Forbes and the New York Times found that when 64 real point-of-care questions were posed to GPT3.5 and GPT4, the responses were not deemed consistently credible. Clinicians could not decide if the generated response agreed with or contradicted established literature nearly 50% of the time. Unlike ChatGPT, whose responses solely rely on information from the internet content on which it was trained, ChatRWD responses additionally rely on existing proprietary technology already used in the Green Button Informatics Consult Service, and leverages real world data from Atropos Evidence Network.
“There is much excitement among the medical community about how chatbots and large language models can be used to advance medicine, but general-purpose applications of these emerging technologies are not exposed to medical records and not intended for medical tasks,” said Dr. Nigam H. Shah, MBBS, PhD, Professor of Medicine at Stanford University and Chief Data Scientist for Stanford Health Care. “Atropos’ usage of language models is in the right context, in the sense that the evidence is still generated by established statistical methods applied to de-identified medical records. It is the interaction with the evidence generation process that is taken over by a language model, driving a simple chat interaction.”
Users of the full suite of solutions on Atropos Health’s Geneva OS – the first operating system for healthcare evidence generation – can expect accelerated time-to-insights and substantial institutional ROI. With Atropos Health, users can expect to conduct real-world evidence-based studies in minutes, down from an industry average of weeks to months. As demonstrated in a recent publication, by speeding up production timelines and optimizing existing resources and staff, life science and healthcare leaders recoup significant cost savings, for patients and their organizations, without impacting clinical outcomes.
Existing Atropos Health users are already receiving access to Geneva OS and the company is accepting beta users for the ChatRWD application. To sign up for beta access and to learn more about Geneva OS and ChatRWD for accelerated evidence-generation, please visit www.atroposhealth.com.
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
